MedWatch

Eli Lilly and Boehringer Ingelheim's Jardiance against heart failure achieves breakthrough designation from FDA

Results from a phase III study with diabetes drug Jardiance are so promising that that the FDA has granted the medication breakthrough designation for fast tracking.

Photo: Mike Blake/REUTERS / X00030

The US Food and Drug Administration (FDA) has designated the drug Jardiance from Eli Lilly and Boehringer Ingelheim the status 'breakthrough,' which fasttracks the application of the substance against a special type of heart failure, Eli Lilly informs in a statement. The FDA further explains the special status with the promising results from a phase III trial with Jardiance in the above indication.

According to Eli Lilly, the study confirms that Jardiance is the first treatment to significantly improve conditions for adults with weakened left ventricle muscles.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs